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CASE REPORT
A 58-year-old man with a ,1 pack-year smoking his-
tory presented with left cervical lymphadenopathy. Excisional 
lymph node (LN) biopsy revealed a squamous-cell carci-
noma (SqCC) (Figure 1). Positron emission tomography 
scan revealed FDG-avid mediastinal and supraclavicular 
LNs and a right upper lobe (RUL) lesion with ground glass 
appearance on computed tomography. Needle aspirate of the 
RUL lesion was not reviewed at our institution. The outside 
report stated no malignant cells were present. other studies 
did not reveal a primary.
With a presumed diagnosis of lung SqCC, the patient was 
treated with chemotherapy with marked response followed by 
a lobectomy and mediastinal LN dissection. Pathologic evalu-
ation identified a 2.9-cm, moderately differentiated, Thyroid 
Transcription Factor 1 (TTF1)1/p63−/CK5/6− adenocar-
cinoma (AD) of the RUL (Figure 2). Mediastinal LNs and 
intrapulmonary lymphatics were extensively involved with 
TTF1−/p631/CK5/61 SqCC. A lung parenchyma SqCC was 
not identified. Molecular studies on the AD revealed wild-
type epidermal growth factor receptor (EGFR) and KRAS. 
Fluorescence in situ hybridization detected rearrangement of 
anaplastic lymphoma kinase (ALK).
Approximately 2 years after surgery, the patient had pro-
gressive disease in the lung and LNs. A repeat biopsy was not 
performed. He was treated with crizotinib and had prolonged 
overall tumor shrinkage lasting 13 months. The lung lesions 
shrank significantly whereas the LNs remained stable in size. 
After progression on crizotinib, rebiopsy of a supraclavicu-
lar LN revealed a TTF1−/p631/CK5/61 SqCC. Cytogenetics 
confirmed persistence of an ALK-rearrangement (Figure 3).
This case illustrates an adenosquamous carcinoma 
(AD-SqCC) in which the primary and metastases have differ-
ent histologies. Although the ability of AD-SqCC to metasta-
size as a single histology is well documented,1 a remarkable 
feature of this case is that despite a thorough search, biphasic 
histology could not be documented in the primary tumor. The 
finding of the ALK rearrangement in both confirms that the 
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FIGURE 1. Squamous histology in cervical lymph node 
metastasis.
FIGURE 2. Adenocarcinoma histology in the resected 
primary tumor. Abundant extracellular mucin and focal 
signet-ring cells are the features typical of ALK-rearranged 
adenocarcinoma.
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primary and metastatic tumors are clonally related. There is 
one similar case of a patient with a resected primary tumor 
composed entirely of SqCC and an AD metastasis, both with 
the same EGFR mutation.2 We hypothesize that these primary 
tumors have a minor component with distinct histology that 
is not represented in histologic sections, but which has an 
enhanced metastatic potential, and is thus solely represented 
at the metastatic sites.
This case challenges the principle of histology-based 
triage for molecular testing. In the last decade, advances have 
been made in the identification of therapeutically relevant 
genetic alterations in EGFR, KRAS, and ALK. These events 
occur almost exclusively in AD but not in SqCC.2 Unlike in 
pure SqCC, in AD-SqCC mutations in EGFR and ALK do 
occur at a rate similar to AD.3–5 AD-SqCC are rare, and their 
diagnosis is difficult because of incomplete sampling on biopsy 
or predominance of a single histology, as illustrated in this 
case. We have reported a series of patients in whom AD-SqCC 
was the underlying cause of samples diagnosed as “SqCC” 
harboring EGFR or KRAS mutations.2 This case expands those 
observations to carcinomas with ALK rearrangements.
Currently, no molecular testing is recommended for 
SqCC of the lung. In patients who have a minimal tobacco his-
tory and a small biopsy or metastatectomy that is diagnosed 
as SqCC we suggest thorough histological examination for 
a component of AD, and to consider molecular testing. This 
approach could identify a mutation for which there is a tar-
geted therapy with proven efficacy.
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FIGURE 3. ALK FISH revealing rearrangement in a cervi-
cal lymph node metastasis with squamous histology. ALK 
rearrangement was also found in the primary tumor with 
adenocarcinoma histology (not shown).
